LifeMine Therapeutics, a biotechnology company led by serial entrepreneur Greg Verdine, said Thursday it raised $263 million in a pair of venture financings that will push a novel, protective treatment for organ transplants deeper into later clinical testing.

LifeMine Therapeutics 是一家由连续创业者格雷格·韦尔迪内（Greg Verdine）领导的生物技术公司，该公司周四表示，已完成两笔风险融资，共筹集2.63亿美元，这将推动一种用于器官移植的新型保护性疗法进入更深入的后期临床试验阶段。

To find that new drug, codenamed “LIFE-001,” LifeMine looked to a billion-year-old place: the fungal genome. It’s the same starting point that led to the first statin, penicillin, and a widely used immunosuppressant called

为寻找代号为“LIFE-001”的新药，LifeMine 将目光投向了一个拥有十亿年历史的领域：真菌基因组。这正是促成他汀类药物、青霉素以及一种广泛使用的免疫抑制剂（名为

cyclosporine

环孢素

. While these and many other medicines are derived from fungi, LifeMine has for years been working to make the discovery process more systematic and repeatable, amassing a database of genomic information in the hopes of uncovering promising drug prospects.

尽管这些以及许多其他药物都源自真菌，但LifeMine公司多年来一直致力于使发现过程更加系统化和可重复，积累了大量的基因组信息数据库，以期发掘有前景的药物候选物。

LIFE-001 is the result of that work. It acts on an enzyme called calcineurin, which is historically tough-to-drug and activates the immune system’s T cells. Multiple treatments, such as

LIFE-001 是该项工作的成果。它作用于一种名为钙调神经磷酸酶（calcineurin）的酶，该酶在药物开发历史上一直颇具挑战性，并能激活免疫系统的 T 细胞。多种治疗方法，例如

tacrolimus

他克莫司

and cyclosporine,

以及环孢素，

prevent the body from rejecting transplanted organs by

防止身体排斥移植器官，通过

blocking calcineurin’s activity in some way. But they work by forcing together two proteins that otherwise wouldn’t latch onto one another, an indirect “molecular glue” mechanism that causes a number of other issues. Tacrolimus, often used in patients receiving a

以某种方式阻断钙调神经磷酸酶的活性。但它们的作用机制是迫使两种原本不会相互结合的蛋白质结合在一起，这是一种间接的“分子胶”机制，会导致许多其他问题。他克莫司常用于接受

kidney transplant

肾移植

, is associated with

与……相关

serious side effects such as tremors, seizures and post-transplant diabetes mellitus.

严重的副作用，如震颤、癫痫发作和移植后糖尿病。

Through its discovery work, LifeMine has come up with a compound, LIFE-001, that instead directly inhibits calcineurin by binding to a site that wasn’t previously seen in the enzyme’s structure. Importantly, the drug doesn’t appear to get into the

通过其发现工作，LifeMine 开发出一种化合物 LIFE-001，该化合物通过与酶结构中此前未被发现的位点结合，直接抑制钙调神经磷酸酶。重要的是，该药物似乎不会进入

brain or other peripheral tissues, which could make it safer than existing treatments

大脑或其他外周组织，这可能使其比现有疗法更安全

.

。

LIFE-001 is also designed as a long-acting injectable, which

LIFE-001 也被设计为一种长效注射剂，

“flattens out the pharmacokinetics, so you don't have this oscillation between too much and too little suppression,' Verdine said in an interview.

“使药代动力学曲线趋于平稳，从而避免抑制作用过强与过弱之间的波动，”韦尔迪内在一次采访中表示。

Serial biotech entrepreneur Greg Verdine is the CEO of LifeMine Therapeutics.

连续生物技术企业家格雷格·韦尔迪内（Greg Verdine）是LifeMine Therapeutics的首席执行官。

Permission granted by LifeMine Therapeutics

LifeMine Therapeutics 授予的许可

LifeMine is evaluating the safety of LIFE-001 in an ongoing Phase 1 study. It plans to advance the experimental drug into a Phase 2 study involving people who have undergone a kidney transplant, as well as a Phase 1b trial of those receiving islet cell transplants to manage conditions such as type 1 diabetes or chronic pancreatitis.

LifeMine 正在一项正在进行的1期临床试验中评估 LIFE-001 的安全性。公司计划将该实验性药物推进至针对肾移植受试者的2期临床试验，以及针对接受胰岛细胞移植以管理1型糖尿病或慢性胰腺炎等疾病的受试者的1b期临床试验。

Data in islet transplant recipients could come by the end of 2027, while results from the kidney transplant study are expected in 2028..

胰岛移植受试者的数据可能在2027年底公布，而肾移植研究的结果预计将在2028年发布。

Following LIFE-001 is a second program for autoimmune disorders. Though LifeMine has explored the possibility of using its lead asset to treat conditions like Crohn’s disease and lupus nephritis, Verdine said it opted not to given the crowded and competitive landscape.

继LIFE-001之后，第二个项目针对自身免疫性疾病。尽管LifeMine已探索利用其主导资产治疗克罗恩病和狼疮性肾炎等疾病的可能性，但Verdine表示，鉴于该领域拥挤且竞争激烈，公司决定不推进这一方向。

“Transplantation is a major opportunity that was hiding in plain sight that everyone just overlooked,” he said.

“移植是一个隐藏在显而易见之处却被所有人忽视的重大机遇，”他说。

Though LifeMine is early in its development journey, the company is considering eventually selling LIFE-001 on its own, according to Verdine. LifeMine hasn’t ruled out an initial public offering, either, though it would wait until accumulating data from its first two human studies.

据Verdine称，尽管LifeMine仍处于其发展历程的早期阶段，但该公司正考虑最终自行销售LIFE-001。LifeMine也未排除首次公开募股（IPO）的可能性，不过它会等到积累完前两项人体研究的数据后再做决定。

Formed in 2017, LifeMine is one of many drug startups co-founded by Verdine, a former Harvard University chemical biologist. Others include two publicly traded drug developers —

LifeMine 成立于 2017 年，是由哈佛大学前化学生物学家 Verdine 联合创立的众多药物初创公司之一。其他公司包括两家公开上市的药物开发商——

Parabilis Medicines

帕拉比利斯医药

and Wave Life Sciences — as well as Warp Drive Bio, which

以及Wave Life Sciences——还有Warp Drive Bio，该公司

Revolution Medicines

革命药物公司

acquired

获得

in 2018

2018年

.

。

In 2023, Verdine’s company inked

2023年，Verdine的公司签署了

a research collaboration with GSK

与葛兰素史克（GSK）的研究合作

. Including the venture funding announced Wednesday, the biotech has raised roughly $580 million in private financing.

包括周三宣布的风险投资在内，这家生物技术公司已筹集约5.8亿美元的私人融资。

About $75 million of that total came from a Series D financing LifeMine raised in the fourth quarter of 2025. The rest is in the form of a $188 million Series E round led by Milky Way Investments and involving Jeff Bezos’ investment firm Bezos Expeditions, Gates Frontier, GV, RA Capital Management and Arch Venture Partners, among others..

其中约7,500万美元来自LifeMine在2025年第四季度完成的D轮融资。其余部分则以1.88亿美元的E轮融资形式到位，该轮融资由Milky Way Investments领投，参投方包括杰夫·贝佐斯的投资公司Bezos Expeditions、Gates Frontier、GV、RA Capital Management和Arch Venture Partners等。